Table 1.
Pre-treatment biopsy PDX by clinical molecular subtype
| Clinical molecular subtype | Total implanteda | Any tumor growth | Verified human breast tumor (%) | pCR | |
|---|---|---|---|---|---|
| no | yes | ||||
| ER-/HER2+ | 20 | 6 | 5 (25.0) | 4/8 | 1/12 |
| ER+/HER2+ | 14 | 5 | 4 (28.6) | 3/11 | 1/3 |
| LumA | 9 | 0 | 0 (0.0) | 0/9 | 0/0 |
| LumB | 30 | 6 | 2 (6.7) | 0/27 | 2/3 |
| LumUnk | 1 | 0 | 0 (0.0) | 0/1 | 0/0 |
| Triple negative | 39 | 21 | 20 (51.3) | 9/17 | 11/22 |
| Total | 113 | 38 | 31 (27.4) | 16/73 | 15/40 |
Abbreviations: PDX patient-derived xenograft, pCR pathological complete response, ER estrogen receptor, HER2 human epidermal growth factor receptor 2, LumA luminal A, LumB luminal B, LumUnk luminal unknown
aAn additional seven tumors were implanted and had growth but were not available for pathological confirmation n